CoChat

The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors

Open access

The DOI matches its Crossref record; 69 of the 71 references it cites were found in a registry or an index.

Abstract

Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for the various HDAC isoenzymes. Several studies have shown that HDAC3, in particular, plays an important role in inflammation and degenerative neurological diseases, but the development of selective HDAC3 inhibitors has been challenging. This review provides an up-to-date overview of selective HDAC3 inhibitors, and aims to support the development of novel HDAC3 inhibitors in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules23030551

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The crystal structure of HDAC3 (PDB code: 4A69, mesh indicates the catalytic site surface) showing only the amino acid residues that differ from HDAC1 and HDAC2 (presented as stick structures). The zinc required for catalysis is shown in grey.
Figure 1 The crystal structure of HDAC3 (PDB code: 4A69, mesh indicates the catalytic site surface) showing only the amino acid residues that differ from HDAC1 and HDAC2 (presented as stick structures). The zinc required for catalysis is shown in grey.CC BY · PubMed Central
Figure 2 Chemical structures of HDAC inhibitors that are FDAapproved for use in cancer therapy.
Figure 2 Chemical structures of HDAC inhibitors that are FDAapproved for use in cancer therapy.CC BY · PubMed Central
Figure 3 The zinc binding group of HDAC inhibitors. (A) The most studied zinc binding groups of HDAC inhibitors. (B) Novel zinc binding groups of HDAC inhibitors.
Figure 3 The zinc binding group of HDAC inhibitors. (A) The most studied zinc binding groups of HDAC inhibitors. (B) Novel zinc binding groups of HDAC inhibitors.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Cited by

See all 71

Metadata

Authors
Cao, F., Zwinderman, M., & Dekker, F.
Affiliations
University of Groningen (NL)
Corresponding author
Dekker, Frank
Venue
Molecules
Publisher
MDPI AG
Published
2018-03-02
Volume
23
Issue
3
Pages
551
ISSN
1420-3049 (ISSN-L)
OpenAlex
W2791709427
Cited by
66
References
71
Citations by year
2026: 7 · 2025: 3 · 2024: 6 · 2023: 11 · 2022: 12 · 2021: 12 · 2020: 4 · 2019: 6 · 2018: 4
FWCI
0.66
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
Funders
  • ERC (309782)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (723.012.005)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords
HDAC3, HDAC3 inhibitors, selective inhibitors, epigenetic drug targets, cancer therapy, inflammation, neurodegenerative diseases
MeSH terms
Vorinostat, Panobinostat, Histone Deacetylase 3, Antineoplastic Agents, Histone Deacetylases, Humans, Hydroxamic Acids, Indoles, Inflammation, Isoenzymes, Neoplasm Proteins, Neoplasms, Structure-Activity Relationship, Sulfonamides, Drug Design, Neurodegenerative Diseases, Epigenesis, Genetic, Depsipeptides, Histone Deacetylase Inhibitors, Chemistry Techniques, Synthetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors. https://app.cochat.ai/papers/10.3390/molecules23030551
The paper
Cao, F., Zwinderman, M., & Dekker, F. (2018). The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors. Molecules. https://doi.org/10.3390/molecules23030551

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.